Background: Coronavirus disease 2019 (COVID-19) has outbroken in Wuhan, China, in December, 2019, and became a global pandemic.No effective antiviral agents were approved for COVID-19. In this study, we aim to evaluate the efficacy and outcomes of Lianhuaqingwen (LH) capsulein patients with COVID-19.
Methods:In this retrospective cohort study, we included 147 hospitalized patients with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)infection between February 4th and April 15th, 2020, in Wuhan Huoshen shan hospital. Patients were grouped as usual treatment alone or combination with LH capsules. Propensity score matching analysis were performed between two groups. Primary outcomes were mortality and duration of hospitalization time. Secondary outcomes included the recovery rate of chest radiological manifestations and abnormal laboratory examinations.
Results: In two groups, 40 pairs patients were matched for analysis. The baseline information and clinical characteristics were comparable. 73 (91.25%) of all 80 patients were older than 50 years old. All patients in LH treatment group and 38 (95%) in usual treatment group were surviving respectively (P = 0.494). The hospitalization time of patients in LH treatment group was significantly shorter than usual treatment group (17.85±6.612vs.20.72±5.01 days, P = 0.032). After treatment, the rate of lung lesions detected by chest computerized tomography (CT) was lower in LH treatment group (30% vs. 55.0%, P = 0.024).
Conclusion: LH capsules were associated with the improved clinical effects, and might be recommended in the treatment practices of COVID-19 patients. Moreover, further evaluation of LH capsules in large population randomized controlled trial is needed.